https://www.onclive.com/view/dr-davids-on-the-significance-of-efficacy-data-for-pirtobrutinib-plus-vr-in-r-r-cll2026-07-10T18:44:58.474Z2026-07-10T18:44:58.474Z https://www.onclive.com/view/dr-ravi-on-the-background-and-rationale-of-the-phase-4-psmatrack-study-in-mhspc2026-07-10T18:28:30.555Z2026-07-10T18:28:30.555Z https://www.onclive.com/view/onclive-weekly-news-quiz-7-10-2026-test-your-knowledge-on-key-updates-in-myeloma-mibc-and-more2026-07-10T18:00:00Z2026-07-10T18:00:00Z https://www.onclive.com/view/ge-healthcare-and-mayo-clinic-aim-to-advance-personalized-cancer-treatment-through-new-theranostics-research-collaboration2026-07-10T16:00:00Z2026-07-10T16:00:00Z https://www.onclive.com/view/fda-approves-pegfilgrastim-biosimilar-for-non-myeloid-malignancies2026-07-10T15:40:00Z2026-07-10T15:40:00Z https://www.onclive.com/view/dr-ho-on-a-phase-3-trial-evaluating-oz-v-in-unresectable-recurrent-or-metastatic-ospcc2026-07-10T14:44:09.367Z2026-07-10T14:44:09.367Z https://www.onclive.com/view/fda-approves-pembrolizumab-plus-enfortumab-vedotin-in-mibc2026-07-10T14:34:20.218Z2026-07-10T14:34:20.218Z https://www.onclive.com/view/risvutatug-rezetecan-shows-os-benefit-over-topotecan-in-relapsed-sclc2026-07-10T13:48:57.912Z2026-07-10T13:48:57.912Z https://www.onclive.com/view/fda-approves-subcutaneous-isatuximab-delivered-via-on-body-delivery-system-for-multiple-myeloma2026-07-10T13:27:45.161Z2026-07-10T13:27:45.161Z https://www.onclive.com/view/live-tumor-board-exploring-novel-targets-and-breakthrough-treatment-strategies-in-extrapulmonary-neuroendocrine-carcinomas2026-07-10T13:24:58.043Z2026-07-10T13:24:58.043Z https://www.onclive.com/view/zanubrutinib-extends-ttnt-os-vs-acalabrutinib-in-real-world-r-r-mcl2026-07-10T13:00:00Z2026-07-10T13:00:00Z https://www.onclive.com/view/frontline-combination-strategies-in-kras-g12c-mutant-nsclc2026-07-10T12:05:00Z2026-07-10T12:05:00Z https://www.onclive.com/view/neuroprotective-rationale-and-emerging-agents-in-alk-positive-nsclc2026-07-10T12:00:00Z2026-07-10T12:00:00Z https://www.onclive.com/view/fda-flashback-breast-cancer-decisions-and-news-from-june-20262026-07-10T12:00:00Z2026-07-10T12:00:00Z https://www.onclive.com/view/ringside-trial-results-and-clinical-implications2026-07-10T12:00:00Z2026-07-10T12:00:00Z https://www.onclive.com/view/dr-ravi-on-barriers-to-psma-pet-in-mhspc2026-07-09T20:20:40.237Z2026-07-09T20:20:40.237Z https://www.onclive.com/view/zoldonrasib-combinations-show-compelling-antitumor-activity-in-ras-g12d-mutant-metastatic-pdac2026-07-09T18:00:16.324Z2026-07-09T18:00:16.324Z https://www.onclive.com/view/fda-approval-insights-nivolumab-plus-avd-for-untreated-classical-hodgkin-lymphoma-with-alex-herrera-md2026-07-09T17:04:47.334Z2026-07-09T17:04:47.334Z https://www.onclive.com/view/dr-bekaii-saab-on-first-line-pemigatinib-in-fgfr2-rearranged-cholangiocarcinoma2026-07-09T16:40:34.931Z2026-07-09T16:40:34.931Z https://www.onclive.com/view/practical-care-coordination-adherence-and-toxicity-management2026-07-09T16:05:00Z2026-07-09T16:05:00Z https://www.onclive.com/view/interpreting-efficacy-data-and-assessing-risk-benefit-in-a-curative-intent-population2026-07-09T16:00:00Z2026-07-09T16:00:00Z https://www.onclive.com/view/novel-antibody-drug-conjugate-eliminates-residual-cancer-cells-in-majority-of-patients-with-b-cell-all2026-07-09T16:00:00Z2026-07-09T16:00:00Z https://www.onclive.com/view/patient-level-data-show-extended-os-advantage-with-dcvax-l-vs-external-controls-in-glioblastoma2026-07-09T15:52:02.899Z2026-07-09T15:52:02.899Z https://www.onclive.com/view/ensartinib-reduces-recurrence-risk-after-resection-in-alk-positive-nsclc2026-07-09T15:50:00Z2026-07-09T15:50:00Z https://www.onclive.com/view/hematologists-detail-practice-shaping-data-that-emerged-at-eha-2026-video-2026-07-09T14:00:00Z2026-07-09T14:00:00Z https://www.onclive.com/view/show-me-the-data-redefining-treatment-paradigms-in-triple-negative-breast-cancer-across-the-disease-continuum2026-07-09T14:00:00Z2026-07-09T14:00:00Z https://www.onclive.com/view/adding-olaparib-to-radium-223-does-not-greatly-affect-pros-or-pain-in-mcrpc2026-07-09T13:00:00Z2026-07-09T13:00:00Z https://www.onclive.com/view/cabozantinib-in-grade-3-neuroendocrine-tumors2026-07-09T12:05:00Z2026-07-09T12:05:00Z https://www.onclive.com/view/mutation-specific-response-data-and-treatment-selection-for-gist2026-06-18T12:05:00.000Z2026-07-09T12:05:00Z https://www.onclive.com/view/regulatory-status-of-gist-treatments-and-practice-implications2026-06-18T12:05:00.000Z2026-07-09T12:00:00Z https://www.onclive.com/view/data-point-to-pirtobrutinib-based-regimens-as-a-new-soc-option-for-r-r-cll2026-07-09T12:00:00Z2026-07-09T12:00:00Z https://www.onclive.com/view/safety-profile-of-cabozantinib2026-07-09T12:00:00Z2026-07-09T12:00:00Z https://www.onclive.com/view/dr-ravi-on-quantitative-results-from-psmatrack-in-mhspc2026-07-08T21:36:03.448Z2026-07-08T21:36:03.448Z https://www.onclive.com/view/stride-plus-tace-improves-response-by-recist-mrecist-in-embolization-eligible-hcc2026-07-08T21:00:00Z2026-07-08T21:00:00Z https://www.onclive.com/view/cracking-the-kras-code-how-daraxonrasib-is-reshaping-pancreatic-cancer-and-beyond2026-07-08T20:03:21.822Z2026-07-08T20:03:21.822Z https://www.onclive.com/view/incb123667-advances-to-phase-3-following-encouraging-activity-in-platinum-resistant-ovarian-cancer2026-07-08T19:00:00Z2026-07-08T19:00:00Z https://www.onclive.com/view/how-a-passion-for-translational-research-fuses-surgery-science-and-phase-1-drug-development-with-d-ross-camidge-md-phd-and-funda-meric-bernstam-md2026-07-08T17:00:00Z2026-07-08T17:00:00Z https://www.onclive.com/view/northwestern-medicine-study-finds-lung-transplant-dramatically-improves-survival-for-patients-with-terminal-lung-cancer2026-07-08T16:00:00Z2026-07-08T16:00:00Z https://www.onclive.com/view/fda-accepts-nda-for-varegacestat-in-desmoid-tumors2026-07-08T14:23:24.268Z2026-07-08T14:23:24.268Z https://www.onclive.com/view/dr-spencer-on-the-potential-role-for-in-vivo-car-t-cell-therapy-in-myeloma2026-07-08T14:05:49.100Z2026-07-08T14:05:49.100Z https://www.onclive.com/view/ctdna-mrd-status-predicts-os-benefit-with-adjuvant-chemotherapy-in-resected-crc-liver-metastases2026-07-08T13:00:00Z2026-07-08T13:00:00Z https://www.onclive.com/view/long-term-treatment-considerations-and-unmet-needs-in-idh-mutant-glioma2026-07-08T12:05:00Z2026-07-08T12:05:00Z https://www.onclive.com/view/awareness-access-and-integrating-clinical-trial-discussions-into-routine-care2026-07-08T12:05:00Z2026-07-08T12:05:00Z https://www.onclive.com/view/tp53-mutations-in-egfr-mutant-and-risk-stratification2026-07-08T12:05:00Z2026-07-08T12:05:00Z https://www.onclive.com/view/clinical-scenario-2-older-patient-with-egfr-mutant-nsclc-and-multiple-comorbidities2026-07-08T12:05:00Z2026-07-08T12:05:00Z https://www.onclive.com/view/managing-induction-toxicity-patient-counseling-and-five-year-survival-data2026-07-08T12:05:00Z2026-07-08T12:05:00Z https://www.onclive.com/view/clinical-scenario-1-young-patient-with-egfr-mutant-nsclc-showing-high-risk-features2026-07-08T12:00:00Z2026-07-08T12:00:00Z https://www.onclive.com/view/the-road-ahead-kras-inhibition-treatment-sequencing-and-practical-implementation-of-emerging-therapies2026-07-08T12:00:00Z2026-07-08T12:00:00Z https://www.onclive.com/view/explaining-ezh2-mechanism-and-epigenetic-regulation-to-non-specialists-and-patients2026-07-08T12:00:00Z2026-07-08T12:00:00Z https://www.onclive.com/view/neoadjuvant-adjuvant-pembrolizumab-yields-efs-benefits-regardless-of-surgical-outcomes-in-hnscc2026-07-08T12:00:00Z2026-07-08T12:00:00Z https://www.onclive.com/view/subcutaneous-amivantamab-and-administration-considerations2026-07-08T12:00:00Z2026-07-08T12:00:00Z https://www.onclive.com/view/treatment-sequencing-and-progression-management-in-idh-mutant-glioma2026-07-08T12:00:00Z2026-07-08T12:00:00Z https://www.onclive.com/view/how-bispecific-t-cell-engager-therapy-works-and-why-hla-status-is-non-negotiable2026-07-08T12:00:00Z2026-07-08T12:00:00Z https://www.onclive.com/view/domvanalimab-zimberelimab-plus-chemotherapy-fails-to-improve-os-in-her2-negative-gastroesophageal-adenocarcinoma2026-07-07T23:25:00Z2026-07-07T23:25:00Z https://www.onclive.com/view/extended-folfox-atezolizumab-duration-linked-with-improved-dfs-in-stage-iii-dmmr-colon-cancer2026-07-07T21:11:35.871Z2026-07-07T21:11:35.871Z https://www.onclive.com/view/bexobrutideg-could-pave-the-way-for-btk-degraders-in-r-r-chronic-lymphocytic-leukemia2026-07-07T20:10:39.337Z2026-07-07T20:10:39.337Z https://www.onclive.com/view/further-integrating-biosimilars-into-oncology-the-role-of-wyost-denosumab-bbdz-in-preventing-cancer-related-skeletal-events-with-bone-metastases-from-solid-tumors2026-07-07T20:00:12.208Z2026-07-07T20:00:12.208Z https://www.onclive.com/view/dr-bekaii-saab-on-the-fda-approval-of-zenocutuzumab-in-nrg1-cholangiocarcinoma2026-07-07T19:42:14.006Z2026-07-07T19:42:14.006Z https://www.onclive.com/view/dr-shah-on-the-significance-of-daybreak-cll-201-and-bexobrutideg-for-the-cll-treatment-paradigm2026-07-07T19:38:45.725Z2026-07-07T19:38:45.725Z https://www.onclive.com/view/esr1-mutations-steer-the-oral-serd-story-in-breast-cancer-with-sara-nunnery-md-msci-and-minhtri-nguyen-md2026-07-07T17:00:00Z2026-07-07T17:00:00Z https://www.onclive.com/view/dana-farber-investigators-report-promising-results-from-phase-2-study-of-targeted-therapy-for-rare-bile-duct-cancer2026-07-07T16:00:00Z2026-07-07T16:00:00Z https://www.onclive.com/view/medical-crossfire-precision-oncology-in-nsclc-translating-her2-and-trop2-innovation-into-practice-changing-care2026-07-07T15:48:30.487Z2026-07-07T15:48:30.487Z https://www.onclive.com/view/ai-finds-new-applications-in-oncologic-surgery-drug-and-biomarker-screening-and-clinical-trial-design2026-07-07T14:05:04.406Z2026-07-07T14:05:04.406Z https://www.onclive.com/view/dr-spencer-on-early-efficacy-data-for-in-vivo-car-t-cell-therapy-in-r-r-myeloma2026-07-07T14:00:00Z2026-07-07T14:00:00Z https://www.onclive.com/view/adagrasib-plus-cetuximab-misses-os-pfs-end-points-in-pretreated-kras-g12c-mutated-crc2026-07-07T13:00:00Z2026-07-07T13:00:00Z https://www.onclive.com/view/hr-positive-her2-negative-metastatic-breast-cancer-molecular-testing-and-targeted-therapy-selection-after-disease-progression2026-07-07T12:15:00Z2026-07-07T12:15:00Z https://www.onclive.com/view/adcs-in-cns-disease-and-managing-patients-with-multiple-biomarkers2026-07-07T12:10:00Z2026-07-07T12:10:00Z https://www.onclive.com/view/the-case-for-first-line-therapy-and-understanding-trop2-as-a-target2026-07-07T12:05:00Z2026-07-07T12:05:00Z https://www.onclive.com/view/early-treatment-access-and-palliative-care-integration-for-patients-with-es-sclc2026-06-23T12:05:00.000Z2026-07-07T12:05:00Z https://www.onclive.com/view/os-benefit-patient-communication-and-frontline-risk-in-dlbcl2026-07-07T12:05:00Z2026-07-07T12:05:00Z https://www.onclive.com/view/safety-tolerability-and-mechanism-of-duvelisib2026-07-07T12:05:00Z2026-07-07T12:05:00Z https://www.onclive.com/view/phase-1-data-highlight-potential-utility-for-in-vivo-car-t-cell-therapy-in-r-r-myeloma2026-07-07T12:00:00Z2026-07-07T12:00:00Z https://www.onclive.com/view/choosing-between-two-frontline-regimens-in-dlbcl2026-07-07T12:00:00Z2026-07-07T12:00:00Z https://www.onclive.com/view/clinical-scenario-cns-only-progression-on-osimertinib-in-egfr-mutated-nsclc2026-07-07T12:00:00Z2026-07-07T12:00:00Z https://www.onclive.com/view/nccn-guideline-updates-and-choosing-a-first-line-adc2026-07-07T12:00:00Z2026-07-07T12:00:00Z https://www.onclive.com/view/limitations-of-phase-1b-data-and-biomarker-development-in-es-sclc2026-06-23T12:05:00.000Z2026-07-07T12:00:00Z https://www.onclive.com/view/primo-trial-design-and-efficacy-in-relapsed-refractory-ptcl2026-07-07T12:00:00Z2026-07-07T12:00:00Z https://www.onclive.com/view/hr-positive-her2-negative-metastatic-breast-cancer-sequencing-strategies-after-cdk4-6-inhibitor-progression2026-07-07T12:00:00Z2026-07-07T12:00:00Z https://www.onclive.com/view/dr-spencer-on-differentiating-factors-for-in-vivo-car-t-cell-therapy-in-myeloma2026-07-06T21:28:14.161Z2026-07-06T21:28:14.161Z https://www.onclive.com/view/fda-issues-crl-to-orviglance-for-liver-metastasis-imaging-in-patients-with-severe-kidney-impairment2026-07-06T20:40:26.861Z2026-07-06T20:40:26.861Z https://www.onclive.com/view/epcoritamab-plus-lenalidomide-rituximab-win-eu-approval-for-r-r-follicular-lymphoma2026-07-06T20:24:32.221Z2026-07-06T20:24:32.221Z https://www.onclive.com/view/dr-bose-on-the-rationale-for-evaluating-sapablursen-in-polycythemia-vera2026-07-06T19:27:13.448Z2026-07-06T19:27:13.448Z https://www.onclive.com/view/dr-rao-on-the-prognostic-value-of-post-surgical-ctdna-status-in-early-tnbc2026-07-06T17:00:00Z2026-07-06T17:00:00Z https://www.onclive.com/view/roswell-park-documents-remarkably-high-success-rate-for-allogeneic-stem-cell-transplants2026-07-06T16:00:00Z2026-07-06T16:00:00Z https://www.onclive.com/view/savolitinib-gains-nmpa-approval-for-met-amplified-gastric-and-gej-adenocarcinoma2026-07-06T15:00:14.010Z2026-07-06T15:00:14.010Z https://www.onclive.com/view/health-canada-green-lights-ropeginterferon-alfa-2b-for-polycythemia-vera2026-07-06T14:42:25.793Z2026-07-06T14:42:25.793Z https://www.onclive.com/view/divarasib-outperforms-first-generation-kras-g12c-inhibitors-in-phase-iii-nsclc-t2026-07-06T13:44:45.106Z2026-07-06T13:44:45.106Z https://www.onclive.com/view/tp53-status-and-time-toxicity-shape-sequencing-decisions-in-egfr-mutated-nsclc2026-07-06T13:00:00Z2026-07-06T13:00:00Z https://www.onclive.com/view/introducing-radioligand-equivalent-terminology2026-07-06T12:05:00Z2026-07-06T12:05:00Z https://www.onclive.com/view/high-risk-disease-management-and-biomarker-guided-decisions2026-07-06T12:05:00Z2026-07-06T12:05:00Z https://www.onclive.com/view/colorectal-cancer-observational-data-and-risk-stratification2026-07-06T12:05:00Z2026-07-06T12:05:00Z https://www.onclive.com/view/her2-positive-early-breast-cancer-balancing-pcr-and-idfs-in-treatment-selection2026-07-06T12:05:00Z2026-07-06T12:05:00Z https://www.onclive.com/view/advantages-of-the-505-b-2-pathway-and-bridging-evidence-requirements2026-07-06T12:00:00Z2026-07-06T12:00:00Z https://www.onclive.com/view/sequoia-long-term-follow-up-and-zanubrutinib-monotherapy-data2026-07-06T12:00:00Z2026-07-06T12:00:00Z https://www.onclive.com/view/rusfertide-maintains-long-term-thromboembolism-control-in-phlebotomy-dependent-polycythemia-vera2026-07-06T12:00:00Z2026-07-06T12:00:00Z https://www.onclive.com/view/her2-positive-early-breast-cancer-reviewing-destiny-breast05-and-residual-disease-management2026-07-06T12:00:00Z2026-07-06T12:00:00Z https://www.onclive.com/view/breast-cancer-ctdna-surveillance-landscape2026-07-06T12:00:00Z2026-07-06T12:00:00Z https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-6-282026-07-05T10:00:00Z2026-07-05T10:00:00Z https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-6-282026-07-04T19:21:00Z2026-07-04T19:21:00Z https://www.onclive.com/view/divesiran-reduces-phlebotomy-burden-and-improves-iron-stores-in-polycythemia-vera2026-07-04T10:00:00Z2026-07-04T10:00:00Z